Clinical Trial Details
— Status: Terminated
Administrative data
NCT number |
NCT03002597 |
Other study ID # |
STUDY19080134 |
Secondary ID |
|
Status |
Terminated |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 2014 |
Est. completion date |
June 2021 |
Study information
Verified date |
July 2023 |
Source |
University of Pittsburgh |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The BrainPort vision device is a visual prosthetic designed for those who are blind. It
enables perception of visual information using the tongue and camera system as a paired
substitute for the eye. Visual information is collected from a video camera and translated
into a gentle vibration that is presented to the subject on the tongue. With training users
perceive shape, size, location and motion of objects in their environment. It is a
functional, non-surgical device developed to demonstrate as an aid to the visually impaired.
The aim of this proposal is to evaluate a non-surgical visual prosthetic (BrainPort vision
device) that enables the blind to appreciate their immediate surroundings and determine the
way the brain interprets the information. Our goal is to determine if the device can be used
in a pediatric population by measuring the subjects' improvement over baseline in any of the
following areas: light detection, light localization, movement perception, and standardized
object recognition tasks after use of the BrainPort.
Description:
Objective:
Our objective is to determine if the functional improvements seen in blind subjects using the
BrainPort can be realized in a pediatric cohort.
Specific Aims:
The aim of this proposal is to evaluate a non-surgical visual prosthetic (BrainPort vision
device) that enables the blind to appreciate their immediate surroundings and determine the
way the brain interprets the information. Our main goal is to determine if the device can be
used in a pediatric population by measuring the subjects' improvement over baseline in any of
the following areas: light detection, light localization, movement perception, and
standardized object recognition tasks after use of the BrainPort.
As a second aim, the investigators will use a multimodal MR scanning session to study the
neurophysiological basis of sensory substitution in children. Under this aim the
investigators will pursue two main objectives. First, the investigators will correlate the
behavioral data with the imaging data in order to detect regions of the brain where structure
and/or function are associated with successful use of sensory substitution devices. Second,
the investigators will utilize these data along with previously collected adult data to model
the effects of prior visual experience on visual cortex plasticity due to blindness.
Background:
The BrainPort vision device is a visual prosthetic designed for those who are blind. It
enables perception of visual information using the tongue and camera system as a paired
substitute for the eye. Visual information is collected from a video camera and translated
into gentle electrical stimulation patterns on the surface of the tongue. With training,
users perceive shape, size, location and motion of objects in their environment. It is a
functional, non-surgical device developed to demonstrate as an aid to the visually impaired.
Tactile sensory systems have proven capable of carrying information to the brain that is
usually acquired visually. Braille and the long cane have provided such information to blind
persons for decades, and in the 1960's it was clearly demonstrated that tactile inputs could
provide access to written print1 and visual images2. The main limitation to the development
of practical vision substitution has been the inadequacy of brain-machine interfaces.
Thirty-five years ago Paul Bach-y-Rita, MD wrote "That a successful sensory substitution
system is not presently in use may not be due to limited functional capabilities of the
brain; it may be due to the fact that an artificial receptor system has not yet been
constructed to challenge the adaptive capacities of the human brain"3.
BrainPort Vision Device Since 1998, Wicab has focused on biomedical engineering research and
development of commercial devices based on its proprietary BrainPort® technology4. The
BrainPort vision device is a visual prosthetic designed for those who are blind.
Numerous previous studies support using the tongue as a sensory substitution channel2,3,5-8.
Our and others' research has revealed that the brain can correctly interpret information from
a sensory substitution device, even when the information is not presented in the same pathway
as the natural sensory system. For example, the optical image actually received by the eye
travels no farther than the retina, which converts the image into spatio-temporal patterns of
action potentials along the optic nerve fibers. By analyzing these impulse patterns, the
brain recreates the image. These impulses are not unique for vision. In fact, all sensory
systems code information using the same 'language': neuronal action potentials. Using the
vision example as a paradigm, sensory substitution requires only that action potentials be
accurately entrained in the alternate sensory information channel. With training, the brain
may learn to appropriately interpret information from the alternate channel and then to
process that information much as it would data from the intact natural sense. Therefore, this
technology benefits users by stimulating the tongue with usable information about their
environment, which some users have described as resembling vision.
Although BrainPort technology stimulates the tongue through the electrode array, the
stimulation is not at all painful; a BrainPort device emits only 11.85 µJ per pulse
(regulatory limit for cutaneously electrical stimulating devices: 300 mJ). In fact, users
often report the sensation as being like champagne bubbles effervescing on the tongue.
Participants using BrainPort devices, whether for several hours each day over the course of a
few weeks or for 20 minutes a day for up to one year, report no discomfort.
Little work has been done using imaging to study blind children. Werth and Seelos used fMRI
to measure evoked activity in the visual cortex of children as evidence of visual function
improvement following field training (Neurpsychologica. 2005. 43(14): 2011). However, to our
knowledge, imaging of blind children to assess plasticity of the visual cortex at such a
young age has not been done. In the short term, imaging of these subjects may improve our
ability to screen for patients who would benefit from sensory substitution devices as well as
to evaluate training paradigms. In the long term, understanding plasticity due to visual
deprivation will be important not just for sensory substitution, but for all vision
restoration strategies in order to identify subjects still capable of processing visual
input. As the investigators attempt to model the effects of prior visual experience on
plasticity in the visual cortex following blindness, children represent a unique and
essential portion of the sample to tease apart the relative effects of blindness duration and
early versus late acquisition.
The BrainPort device has been approved by the FDA since June of 2015.
Significance:
The BrainPort vision device is a visual prosthetic designed for those who are blind. It
enables perception of visual information using the tongue and camera system as a paired
substitute for the eye. Visual information is collected from a video camera and translated
into gentle electrical stimulation patterns on the surface of the tongue. With training users
perceive shape, size, location and motion of objects in their environment. It is a
functional, non-surgical device developed to demonstrate as an aid to the visually impaired.
The BrainPort vision device is the only new technology likely available in the near term to
address safety and mobility issues resulting from blindness.
Our results have shown that the use of the BrainPort results in behavioral improvements as
well as activation in visual cortical regions using fMRI and PET scans in adults. A trial
which seeks to determine if functional abilities can also be improved in a pediatric cohort
is justifiable for the following reasons:
1. Neuroplasticity is highest in childhood, and the visually deprived brain is likely to be
most receptive to alternative sensory stimulation in this age group.
2. The BrainPort is non-invasive.
3. Other than gene therapy for Leber's Congenital Amaurosis, there are no alternatives to
restoring vision for the blind children at this time.
4. The BrainPort already has CE Mark approval and pending FDA approval (final safety study
documents submitted to the FDA August 2013), and should be available for purchase by
2014, at least in Europe and Canada. Whether the device could be useful in a pediatric
population is an important clinical question.
5. The relation of the anticipated benefit to the risk presented by the study is at least
as favorable to the subjects as that provided by available alternative approaches (blind
training).